Leidos Holdings has awarded Pfenex a subcontract to support the development of an anthrax vaccine containing its recombinant protective antigen (rPA) and a novel, immune-enhancing adjuvant. The main contract was awarded to Leidos by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to improve the efficacy of both anthrax and West Nile virus vaccines.   Pfenex will provide its rPA, which will be evaluated in various formulations wi...